**Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications Reproductive Health Implications**

**Polycystic Ovary Syndrome, Pathophysiology, and** 

DOI: 10.5772/intechopen.70848

Bassim Alsadi Bassim Alsadi Additional information is available at the end of the chapter

[83] Malla B, Zaugg K, Vassella E, Aebersold DM, Dal Pra A. Exosomes and exosomal microRNAs in prostate cancer radiation therapy. International Journal of Radiation

[84] Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research.

[85] Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clinical Cancer Research: An Official

[86] Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate

[87] Kharmate G, Hosseini-Beheshti E, Caradec J, Chin MY, Tomlinson Guns ES. Epidermal growth factor receptor in prostate cancer derived exosomes. PLoS One. 2016;11(5):e0154967

[88] Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A. Can urinary exosomes act as treatment response markers in prostate cancer? Journal of Translational

[89] Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, Lugini L, Borsellino G, Gentilucci A, Pierella F, Marzio V, Sciarra A, Battistini L, Fais S. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.

[90] Porpiglia F, De Luca S, Bertolo R, Passera R, Mele F, Manfredi M, Amparori D, Morra I, Fiori C. Robot-Assisted extended pelvic lymph nodes dissection for prostate cancer: Personal Surgicaal technique outcomes. International Braz J Urol. 2015;41(6):1209-12019

[91] Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. The New England Journal of Medicine. 2016;

[92] National Cancer Institute. Prostate Cancer Treatment (PDQ®) – Patient Version [Internet]. [Update 2016 Jul 7]. Available from: https://www.cancer.gov/types/prostate/patient/prostate-

[93] Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. The Lancet Oncology. 2010;10:981-991

[94] UpToDate [Internet]. Dawson NA (MD): Patient education: Treatment for advanced

[95] Zytiga: Abiratenone acetate. Janssen-Cilag Oncology. Available From: https://www.zytiga.

prostate cancer (Beyound the Basics). [Update 2017 Aug].

Journal of the American Association for Cancer Research. 2002;8(12):3870-3876

cancer. American Journal of Clinical Oncology. 2010;33(6):609-613

Oncology, Biology, Physics. 2017;98(5):982-995

2000;6(5):2053-2063

202 Pathophysiology - Altered Physiological States

Medicine. 2009;7:4

375:1415

com/

Cancer Letters. 2017;403:318-329

treatment-pdq#section/\_142.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/intechopen.70848

#### **Abstract**

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age. The clinical picture characterized by both endocrine disorders (hyperandrogenism, menstrual cycle disorders, obesity) and metabolic alteration with implications for women's health and reproductive and metabolic consequences. Leventhal described for the first time a syndrome characterized by polycystic ovaries associated with menstrual cycle disorders, hirsutism, and obesity. The pathophysiology and other metabolic disorders that make the PCOS more complex than originally described are the most common cause of infertility linked to chronic anovulation. In fact, this is a multifactorial disorder that involves the hypothalamus, pituitary, ovary, adrenal, and peripheral adipose tissues, which are simultaneously involved in the pathogenesis of the syndrome.

**Keywords:** infertility, polycystic ovary (PCO), polycystic ovarian syndrome (PCOS), menstrual irregularities, acne, hirsutism, anovulation, obesity, hyperandrogenism, insulin resistance and hyperinsulinemia, metformin
